Source comparison
Desensitisation Dynamics: GHS-R1a Internalisation vs GHRHR-SOCS3
The desensitisation profiles of Hexarelin and CJC-1295 represent one of the most important distinctions for longitudinal research protocols. Hexarelin, due to its very high GHS-R1a affinity, drives rapid receptor internalisation via GRK2-β-arrestin-2 pathways
This comparison does not assign a generated winner or score.
- The desensitisation profiles of Hexarelin and CJC-1295 represent one of the most important distinctions for longitudinal research protocols. Hexarelin, due to its very high GHS-R1a affinity, drives rapid receptor internalisation via GRK2-β-arrestin-2 pathways — with GHS-R1a surface expression declining by 44–52% after 5 consecutive daily doses at 10 µg/kg in rat pituitary preparations. GH peak amplitude decreases in parallel: Day 1 → Day 5, from 52 ng/mL to 29 ng/mL (−44%). This is substantially greater desensitisation than Ipamorelin (−22%, Day 1 → Day 5) or GHRP-6 (−28%), attributable to Hexarelin’s superior GHS-R1a affinity driving more efficient receptor internalisation.
- CJC-1295 non-DAC produces minimal GHRHR desensitisation with pulsatile administration — GHRHR surface expression in somatotrophs remains at 88–94% of baseline after 7 days of once-daily administration. However, CJC-1295 DAC produces a distinct desensitisation mechanism: not GHRHR internalisation, but hepatic SOCS3 upregulation via sustained STAT5 signalling in response to continuously elevated GH. This SOCS3-mediated signal attenuation reduces IGF-1 synthesis by 22–28% after 4 weeks, and is reversible within 2–3 weeks of cessation — creating a “tolerance window” concept relevant to DAC protocol design.
- In practical research terms: Hexarelin is best used in acute (single-dose or limited-dose) GH secretion studies where maximal GH amplitude is required and cortisol confounding can be controlled (adrenalectomy + corticosterone replacement, or mifepristone 10 mg/kg controls). CJC-1295 non-DAC is optimal for longitudinal pulsatile GH research. CJC-1295 DAC is appropriate for sustained IGF-1 exposure protocols where pulsatility is deliberately eliminated as a variable.